GlassScriptPhysician profile
Elizabeth C Andrus
NPI 1295194967
$2,711.33
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,822 · 2022: $644 · 2023: $231 · 2024: $15.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $245.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $389.16 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $324.34 | 2021-2022 | |
| Abbvie INC. | $272.57 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $236.85 | 2021-2023 | |
| Esperion Therapeutics, INC. | $217.78 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $202.55 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $167.85 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.57 | 2021-2022 | |
| Amgen INC. | $131.66 | 2021-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $118.02 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $115.32 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.90 | 2021-2022 | |
| Glaxosmithkline, LLC. | $66.01 | 2021-2023 | Trelegy Ellipta |
| Biohaven Pharmaceutical Holding Company LTD. | $58.75 | 2022 | |
| Pfizer INC. | $44.59 | 2021-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $33.56 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $18.81 | 2023 | Ajovy |
| Axsome Therapeutics, INC. | $18.38 | 2023 | Auvelity |
| Medicure Pharma INC. | $18.34 | 2021 | |
| Abbott Laboratories | $16.94 | 2021 | |
| Ironwood Pharmaceuticals, INC | $16.70 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.29 | 2021 | |
| Genentech USA, INC. | $8.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Andrus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.